Hansoh Pharmaceutical Announces HS-10390 Tablet Receives IND Approval from NMPA for FSGS and IgA Nephropathy

Hansoh Pharma announced on January 9 that HS-10390 Tablets, a Class 1 new drug independently developed by its subsidiaries Changzhou Humon Pharmaceutical Co., Ltd. and Shanghai Hansoh BioMedical Co., Ltd., has received the clinical trial notification issued by the National Medical Products Administration of the People's Republic of China. The drug is intended for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy, with specific indications to be determined after clinical trials.